Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly somatrogon versus daily Genotropin treatment burden study in children with growth hormone deficiency
2018-000918-38Phase 3Unknown
- Sponsor
- Pfizer
- Start
- Nov 2018
- Modality
- Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of somatrogon and somatropin in growth hormone deficiency (GHD) (2 arms), sponsored by Pfizer. Primary endpoint: Overall Life Interference total score difference. Status: unknown.
02
Drugs
somatrogonsomatropin
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on 2018-000918-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000918-38.